Prof Sharad Singhal, Beckman Research Institute of City of Hope , United States
Sharad S. Singhal, Ph.D., born September 12, 1963, in Agra, India, is a Professor in the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center. He earned his Ph.D. in Biochemistry from the Central Drug Research Institute, India. Dr. Singhal’s research focuses on protein chemistry, drug resistance mechanisms, and the role of RLIP76 in cancer biology. He has received multiple prestigious grants from the Department of Defense for his innovative work in cancer therapeutics.
Publication Profile
Scopus
Education
Sharad S. Singhal completed his undergraduate studies in Chemistry, Zoology, and Botany followed by a Master’s degree in Organic Chemistry from Agra University, India. He earned his Ph.D. in Biochemistry from the Central Drug Research Institute, Lucknow, India, under the supervision of Dr. Chanan Singh. His doctoral research focused on enzyme modulation by macro-ionic interactions, particularly starch-splitting enzymes.
Experienceย
Dr. Singhal’s academic career includes positions at various esteemed institutions. He served as an Assistant Professor at the University of Texas Medical Branch, Galveston, and later as an Associate Professor at the University of Texas at Arlington. He also held a position as Associate Professor at the University of North Texas Health Science Center before joining City of Hope Comprehensive Cancer Center as a Research Professor.
Awards and Honors
Sharad S. Singhal has been recognized for his contributions to cancer research with awards such as the Junior and Senior Research Fellowships from the Council of Scientific and Industrial Research, India. He has received significant research funding from the Department of Defense, including awards for studies on breast cancer, melanoma, ovarian cancer, and small cell lung cancer. Dr. Singhal’s work has been pivotal in advancing understanding of RLIP76 and its implications in cancer therapy.
Research focus
Dr. Singhal’s research interests lie in protein chemistry, enzymology, and understanding drug resistance mechanisms in cancer cells. His primary focus is on RLIP76, a multi-specific transporter that plays a crucial role in transporting chemotherapeutic drugs and glutathione-electrophile conjugates in mammalian cells. His recent work explores RLIP76 inhibition as a strategy for inducing apoptosis in various cancer types, including melanoma, breast cancer, and ovarian cancer. He employs a multidisciplinary approach combining genetic, molecular, and proteomic techniques to investigate the molecular basis of cancer and develop novel therapeutic strategies.
Publication Top Notes